This quarter we zero in on rheumatology — a field where a single denied infusion can cost a practice $4,000 or more, and where the gap between clinical complexity and payer logic is wider than almost anywhere else in medicine. The specialty sits at the intersection of three converging pressures: high-cost biologic drugs, aggressive payer utilization management, and Medicare reimbursement policies that haven’t kept pace with the actual cost of delivering care.
A Scenario from the Field
A rheumatology practice in the Southwest has been administering infliximab infusions for a patient with refractory rheumatoid arthritis for two years. The treatment is working. Then, without warning, the Medicare Advantage plan downcodes the infusion claim and flags the biologic for re-authorization — requiring fresh documentation of step therapy failure, current disease activity scores, and lab values going back six months. The prior auth takes three weeks. The patient misses a dose. The practice absorbs the administrative cost. Sound familiar?
This isn’t a billing error. It’s the new operating reality for rheumatology practices. The specialty’s revenue model depends heavily on biologics administered under buy-and-bill arrangements — where the practice purchases the drug and bills Medicare Part B for both the drug (J-code) and the infusion service. Medicare reimbursement is tied to Average Sales Price (ASP) calculations, and 2026 brought new pressure: if the Medicare Drug Price Negotiation Program’s Maximum Fair Price gets folded into ASP, reimbursement rates could fall below acquisition cost, forcing some practices to administer drugs at a loss.
Meanwhile, payer utilization management is intensifying. Prior authorization requirements are expanding, criteria change quarterly without notice, and the WISeR AI prior authorization pilot — now live in Arizona — introduces algorithmic denial review for Medicare patients, adding a new layer of unpredictability for practices managing high-cost drug approvals. The ACR has formally opposed the ASP methodology change and is actively lobbying for prior auth reform — but until policy catches up, the operational burden falls on the practice.
The Pressure Points This Quarter
Buy-and-Bill Risk
Buy-and-bill is under siege
Rheumatology’s revenue model depends heavily on biologics administered under buy-and-bill arrangements. Medicare reimbursement is tied to ASP calculations, and a proposed policy change — folding the Maximum Fair Price into ASP — could push reimbursement below acquisition cost for some drugs. Biologics like Remicade can run $3,800 per infusion and Stelara $12,000 per dose. A single documentation or coding misalignment on a J-code can result in denied reimbursement on a drug that cost the practice thousands. The ACR has formally opposed the ASP methodology change.
ACR formally opposed the new ASP methodology · Buy-and-bill margin at risk
Prior Auth Complexity
Prior auth: more frequent, more complex, now algorithmic
97% of Medicare Advantage plans require prior authorization for biologic DMARDs. Payer-specific criteria change quarterly — what cleared last year may fail this year. The new WISeR AI prior authorization pilot, live in Arizona and five other states, introduces algorithmic denial review for Medicare patients through 2031. Incomplete documentation of step therapy failure, disease activity scores, or lab values going back 6+ months is now enough to trigger a denial on a treatment that’s been working for years.
18–22% of denied specialty meds: patients never access treatment
Biosimilar Billing
Biosimilar complexity adds a new billing layer
As payers push biosimilar adoption — adalimumab biosimilars, infliximab biosimilars — practices must navigate new HCPCS codes, NDC reporting requirements, and formulary-specific coverage rules. Some biosimilars are reimbursed below acquisition cost, creating a financial trap for practices without real-time payer policy visibility. Payers are pushing substitution, but the billing infrastructure to support it cleanly is lagging behind the clinical reality.
2026: new J-code scrutiny + NDC reporting required for biosimilars
Opportunity
CCM and RPM — recurring revenue hiding in plain sight
Congress extended telehealth flexibilities two more years in early 2026, including virtual supervision. For rheumatology, this opens real billing opportunity: Chronic Care Management (CCM) and Remote Patient Monitoring (RPM) codes apply directly to the chronic autoimmune patient population. Most rheumatology practices are delivering the care that qualifies — phone check-ins, medication adjustments, care coordination — they just aren’t billing for it. For a panel of 150–200 qualifying patients, CCM billing alone can add $8,000–$15,000 per month in recurring revenue.
Telehealth extended 2 more years · New Advanced Primary Care Management codes available
Three Actions for This Quarter
1
Build a biologic prior auth playbook — by payer.
Generic PA workflows fail in rheumatology. Each Medicare Advantage plan has different step therapy criteria, documentation requirements, and appeal timelines. Map them. A denial on a $12,000 infusion that takes three weeks to resolve isn’t a paperwork problem — it’s a cash flow event. Know what each payer needs before the claim goes out, not after it comes back.
2
Audit your J-code and NDC reporting monthly.
NDC reporting errors and unit miscalculations on biologic claims are among the most common denial root causes in rheumatology. A single documentation or coding misalignment can result in denied reimbursement on a drug that cost the practice thousands. Monthly audits catch patterns before they compound into material AR problems.
3
Start billing CCM and RPM if you aren’t already.
Most rheumatology practices are delivering the care that qualifies — they just aren’t capturing it. For a panel of 150–200 chronic patients, CCM billing alone can add $8,000–$15,000 per month in revenue with no additional clinical visits required. The two-year telehealth extension locks in favorable reimbursement to build this now.
Work with Vaqya
Is your rheumatology billing working as hard as your clinical team?
Vaqya’s RCM specialists work with physician practices across specialties to reduce denials, recover underpayments, and build the revenue cycle infrastructure that keeps independent practices independent. Our team brings specialty-trained coders who understand the biologic billing environment, payer-by-payer prior auth requirements, and the 2026 fee schedule changes affecting rheumatology.
Let’s talk →